Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 13,610 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Advanced Solid Tumor, Breast Cancer
Interventions: CFI-402257, Fulvestrant; Drug
Lead sponsor: Treadwell Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Columbus, Ohio • San Antonio, Texas • West Valley City, Utah + 1 more

Conditions: Breast Cancer
Interventions: cyclophosphamide, doxorubicin, paclitaxel; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metastatic Breast Cancer
Interventions: Approved therapy will be assigned based on molecular profile and RPMA results; Drug
Lead sponsor: Translational Drug Development; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Scottsdale, Arizona • Fairfax, Virginia • Spokane, Washington

Conditions: Breast Cancer
Interventions: PET/MRI; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 20 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis
Interventions: Descartes-08; Drug
Lead sponsor: Cartesian Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • St Louis, Missouri • Cincinnati, Ohio

Conditions: Actinic Keratosis
Interventions: PEP005 Topical gel; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 8
States / cities: Tucson, Arizona • San Diego, California • Orange Park, Florida + 5 more

Conditions: Breast Cancer
Interventions: Fulvestrant, Tamoxifen; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: New York, New York

Conditions: Melasma
Interventions: Tranexamic Acid; Drug
Lead sponsor: Laser and Skin Surgery Center of New York; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Systemic Sclerosis, Scleroderma
Interventions: Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New Brunswick, New Jersey + 1 more

Conditions: Bladder Carcinoma, Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Malignant Female Reproductive System Neoplasm, Malignant Neoplasm
Interventions: Communication Intervention, Educational Intervention, Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Duarte, California

Conditions: Breast Cancer
Interventions: AeroForm Tissue Expander; Device
Lead sponsor: AirXpanders, Inc.; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: Greenbrae, California • San Jose, California • Fort Lauderdale, Florida + 4 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Povorcitinib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 37
States / cities: Phoenix, Arizona • Arkansas City, Arkansas • Fort Smith, Arkansas + 32 more

Conditions: Hereditary Angioedema (HAE)
Interventions: navenibart, Placebo; Drug
Lead sponsor: Astria Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 15 more

Conditions: Obesity, Breast Cancer
Interventions: Walking+simulated-altitude, Walking (control); Other · Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Psoriatic Arthritis
Interventions: Apremilast 20mg, Apremilast 30mg, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 30
States / cities: Phoenix, Arizona • Palm Desert, California • Doral, Florida + 26 more

Conditions: Atopic Dermatitis
Interventions: tapinarof cream, 1%, vehicle cream; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 2 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 57
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 49 more

Conditions: Breast Cancer
Interventions: ZN-c5, Abemaciclib; Drug
Lead sponsor: Zeno Alpha Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Gilbert, Arizona • Charleston, South Carolina

Conditions: Breast Cancer, Colon Cancer
Interventions: Patient Navigation, Clinic Staff; Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 1,267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer, Respiratory Gating, Prone
Interventions: CT simulation; Other
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Atopic Dermatitis
Interventions: NM26-2198, Placebo; Biological · Other
Lead sponsor: Yellow Jersey Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Fountain Valley, California • Glendale, California • San Diego, California + 3 more

Conditions: Hereditary Angioedema (HAE)
Interventions: ecallantide, Phosphate Buffer Saline (PBS),; Drug
Lead sponsor: Shire; Industry
Eligibility: 10 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Wheaton, Maryland

Conditions: Breast Cancer, Blood Loss, Surgical
Interventions: Tranexamic acid, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Lipoatrophy, Aging, Wrinkles
Interventions: SVF; Biological
Lead sponsor: Antria; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Greensburg, Pennsylvania

Conditions: Moderate to Severe Chronic Plaque Psoriasis
Interventions: AbGn-168H, placebo; Biological
Lead sponsor: AbGenomics B.V Taiwan Branch; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Boynton Beach, Florida + 11 more

Search by objective public record fields.

CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer

A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel

Pilot Study Using Molecular Profiling to Find Potential Targets & Select Treatments for Pts With Met br ca

Initial Assessment of 18FDG-PET/MRIin Determining the Extent of Systemic Disease in Breast Cancer Patients

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2

Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

Oral Tranexamic Acid and Laser for Treatment of Melasma

Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis

PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers

AirXpanders AeroForm Tissue Expander System for Breast Reconstruction

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

A Study of Navenibart in Participants With Hereditary Angioedema

Simulated-altitude to Optimize Aerobic Exercise Among Breast Cancer Survivors With Limited Mobility

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)

A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer

Patient Navigator Project

Prone Whole-Breast RadiationTherapy Versus Supine Whole-Breast Radiation Therapy Imaging

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

Role of TXA in Patients Undergoing Breast Free Flap Reconstruction

Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells

Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients